{"id":"ida-ivermectin-dec-albendazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea)"},{"rate":null,"effect":"Lymphadenitis (from parasite death)"},{"rate":null,"effect":"Arthralgia/myalgia"}]},"_chembl":{"chemblId":"CHEMBL1483","moleculeType":"Small molecule","molecularWeight":"265.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ivermectin acts as a GABA-gated chloride channel agonist, causing paralysis in nematodes and arthropods. DEC immobilizes microfilariae and enhances immune-mediated clearance. Albendazole inhibits β-tubulin polymerization, disrupting microtubule assembly essential for parasite survival. The combination targets multiple parasite species and life stages simultaneously.","oneSentence":"IDA is a triple-drug combination that paralyzes and kills parasitic worms through multiple mechanisms: ivermectin and DEC (diethylcarbamazine) target neuromuscular function in microfilariae, while albendazole disrupts microtubule formation in helminths.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:25.651Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphatic filariasis (mass drug administration)"},{"name":"Onchocerciasis (river blindness)"},{"name":"Co-infections with multiple helminth and filarial species"}]},"trialDetails":[{"nctId":"NCT04410406","phase":"PHASE3","title":"Moxidectin for LF, Cote d'Ivoire (DOLF)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-08-20","conditions":"Lymphatic Filariasis","enrollment":164},{"nctId":"NCT06070116","phase":"PHASE2","title":"Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-04-05","conditions":"Onchocercal Subcutaneous Nodule, Onchocerciasis, Onchocerciasis, Ocular","enrollment":300},{"nctId":"NCT07159373","phase":"PHASE3","title":"Better Options for Lymphatic Filariasis Treatment","status":"NOT_YET_RECRUITING","sponsor":"Medicines Development for Global Health","startDate":"2026-03","conditions":"Lymphatic Filariasis, Scabies, Strongyloidiasis","enrollment":5100},{"nctId":"NCT04188301","phase":"PHASE2","title":"Safety and Efficacy of IDA for Onchocerciasis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-12-06","conditions":"Onchocerciasis","enrollment":154},{"nctId":"NCT02845713","phase":"PHASE1","title":"Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2016-04-17","conditions":"Wuchereria Bancrofti Infection","enrollment":66},{"nctId":"NCT03676140","phase":"PHASE3","title":"Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )","status":"COMPLETED","sponsor":"Lihir Medical Centre","startDate":"2018-10-01","conditions":"Trachoma, Yaws, Lymphatic Filariases","enrollment":20000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IDA - Ivermectin + DEC + albendazole","genericName":"IDA - Ivermectin + DEC + albendazole","companyName":"Medicines Development for Global Health","companyId":"medicines-development-for-global-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IDA is a triple-drug combination that paralyzes and kills parasitic worms through multiple mechanisms: ivermectin and DEC (diethylcarbamazine) target neuromuscular function in microfilariae, while albendazole disrupts microtubule formation in helminths. Used for Lymphatic filariasis (mass drug administration), Onchocerciasis (river blindness), Co-infections with multiple helminth and filarial species.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}